Lack of Evidence Regarding Markers Identifying Acute Heart Failure in Patients with COPD: An AI-Supported Systematic Review
Sanne van Dijk,Marjolein Brusse-Keizer,Charlotte Bucsán,Eline Ploumen,Wendy van Beurden,Job van der Palen,Carine Doggen,Anke Lenferink
DOI: https://doi.org/10.2147/copd.s437899
2024-02-23
International Journal of COPD
Abstract:Sanne HB van Dijk, 1, 2 Marjolein GJ Brusse-Keizer, 1, 3 Charlotte C Bucsán, 2, 4 Eline H Ploumen, 1, 5 Wendy JC van Beurden, 2 Job van der Palen, 3, 4 Carine JM Doggen, 1, 6 Anke Lenferink 1, 2, 6 1 Health Technology & Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; 2 Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, the Netherlands; 3 Medical School Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 4 Cognition, Data & Education, Faculty of Behavioural, Management & Social Sciences, University of Twente, Enschede, the Netherlands; 5 Department of Cardiology, Medisch Spectrum Twente, Enschede, the Netherlands; 6 Clinical Research Centre, Rijnstate Hospital, Arnhem, the Netherlands Correspondence: Anke Lenferink, Health Technology & Services Research, Technical Medical Centre, University of Twente, Hallenweg 5, Enschede, NH, 7522, the Netherlands, Tel +31 0534896311, Email Background: Due to shared symptoms, acute heart failure (AHF) is difficult to differentiate from an acute exacerbation of COPD (AECOPD). This systematic review aimed to identify markers that can diagnose AHF underlying acute dyspnea in patients with COPD presenting at the hospital. Methods: All types of observational studies and clinical trials that investigated any marker's ability to diagnose AHF in acutely dyspneic COPD patients were considered eligible for inclusion. An AI tool (ASReview) supported the title and abstract screening of the articles obtained from PubMed, Scopus, Web of Science, the Cochrane Library, Embase, and CINAHL until April 2023. Full text screening was independently performed by two reviewers. Twenty percent of the data extraction was checked by a second reviewer and the risk of bias was assessed in duplicate using the QUADAS-2 tool. Markers' discriminative abilities were evaluated in terms of sensitivity, specificity, positive and negative predictive values, and the area under the curve when available. Results: The search identified 10,366 articles. After deduplication, title and abstract screening was performed on 5,386 articles, leaving 153 relevant, of which 82 could be screened full text. Ten distinct studies (reported in 16 articles) were included, of which 9 had a high risk of bias. Overall, these studies evaluated 12 distinct laboratory and 7 non-laboratory markers. BNP, NT-proBNP, MR-proANP, and inspiratory inferior vena cava diameter showed the highest diagnostic discrimination. Conclusion: There is not much evidence for the use of markers to diagnose AHF in acutely dyspneic COPD patients in the hospital setting. BNPs seem most promising, but should be interpreted alongside imaging and clinical signs, as this may lead to improved diagnostic accuracy. Future validation studies are urgently needed before any AHF marker can be incorporated into treatment decision-making algorithms for patients with COPD. Protocol Registration: CRD42022283952. Keywords: COPD, chronic heart failure, biomarkers, systematic review, differential diagnosis Chronic obstructive pulmonary disease (COPD) is the third most important cause of death worldwide, 1 and known for progressive deterioration of lung function. 2 In 8% to 23% of COPD patients, comorbid chronic heart failure (CHF) is diagnosed, 3 doubling their risk of death and reducing their quality of life. 4 The coexistence of COPD and CHF is not surprising, given that they share several risk factors, smoking giving the highest risk. 3 Both COPD and CHF are chronic progressive diseases characterized by periods of deteriorated symptoms. However, acute exacerbations of COPD (AECOPD) and acute heart failure (AHF) require different additional treatment. In an acute situation, diagnosis of AHF in COPD patients can be particularly difficult, given that AECOPD and AHF share symptoms such as acute worsening of dyspnea, 5 but also often occur simultaneously. 6 A systematic review published in 2018 showed that none of the signs and symptoms, with which acutely dyspneic patients present at the emergency department (ED), are acceptably sensitive nor specific to rule in or out AECOPD and AHF. 7 Although this review did not investigate other diagnostic approaches besides signs and symptoms, 7 it endorses that relying solely on signs and symptoms is insufficient. Furthermore, most laboratory tests are neither sensitive nor specific enough to rule in or out cardiac or lung disease as the caus -Abstract Truncated-
respiratory system